The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery

Research output: Contribution to journalJournal articlepeer-review

Standard

The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery. / Hindsø, Morten; Hedbäck, Nora; Svane, Maria S.; Møller, Andreas; Martinussen, Christoffer; Jørgensen, Nils B; Dirksen, Carsten; Gasbjerg, Lærke S; Kristiansen, Viggo B.; Hartmann, Bolette; Rosenkilde, Mette M.; Holst, Jens J; Madsbad, Sten; Bojsen-Møller, Kirstine N.

In: Diabetes, Vol. 72, No. 3, 2023, p. 336–347.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Hindsø, M, Hedbäck, N, Svane, MS, Møller, A, Martinussen, C, Jørgensen, NB, Dirksen, C, Gasbjerg, LS, Kristiansen, VB, Hartmann, B, Rosenkilde, MM, Holst, JJ, Madsbad, S & Bojsen-Møller, KN 2023, 'The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery', Diabetes, vol. 72, no. 3, pp. 336–347. https://doi.org/10.2337/db22-0568

APA

Hindsø, M., Hedbäck, N., Svane, M. S., Møller, A., Martinussen, C., Jørgensen, N. B., Dirksen, C., Gasbjerg, L. S., Kristiansen, V. B., Hartmann, B., Rosenkilde, M. M., Holst, J. J., Madsbad, S., & Bojsen-Møller, K. N. (2023). The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery. Diabetes, 72(3), 336–347. https://doi.org/10.2337/db22-0568

Vancouver

Hindsø M, Hedbäck N, Svane MS, Møller A, Martinussen C, Jørgensen NB et al. The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery. Diabetes. 2023;72(3):336–347. https://doi.org/10.2337/db22-0568

Author

Hindsø, Morten ; Hedbäck, Nora ; Svane, Maria S. ; Møller, Andreas ; Martinussen, Christoffer ; Jørgensen, Nils B ; Dirksen, Carsten ; Gasbjerg, Lærke S ; Kristiansen, Viggo B. ; Hartmann, Bolette ; Rosenkilde, Mette M. ; Holst, Jens J ; Madsbad, Sten ; Bojsen-Møller, Kirstine N. / The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery. In: Diabetes. 2023 ; Vol. 72, No. 3. pp. 336–347.

Bibtex

@article{91257bb248c948a0b723126d20503775,
title = "The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery",
abstract = "Enhanced secretion of glucagon-like peptide-1 (GLP-1) seems to be essential for improved postprandial β-cell function after Roux-en-Y gastric bypass (RYGB) but is less studied after sleeve gastrectomy (SG). Moreover, the role of the other major incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), is relatively unexplored after bariatric surgery. We studied the effects of separate and combined GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) blockade during mixed meal tests in unoperated (CON), SG-operated, and RYGB-operated people with no history of diabetes. Postprandial GLP-1 concentrations were highest after RYGB but also higher after SG compared with CON. In contrast, postprandial GIP concentrations were lowest after RYGB. The effect of GLP-1R versus GIPR blockade differed between groups. GLP-1R blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the surgical groups but had no effect in CON. GIPR blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the CON and SG groups but had no effect in the RYGB group. Our results support that GIP is the most important incretin hormone in unoperated people, whereas GLP-1 and GIP are equally important after SG, and GLP-1 is the most important incretin hormone after RYGB.",
author = "Morten Hinds{\o} and Nora Hedb{\"a}ck and Svane, {Maria S.} and Andreas M{\o}ller and Christoffer Martinussen and J{\o}rgensen, {Nils B} and Carsten Dirksen and Gasbjerg, {L{\ae}rke S} and Kristiansen, {Viggo B.} and Bolette Hartmann and Rosenkilde, {Mette M.} and Holst, {Jens J} and Sten Madsbad and Bojsen-M{\o}ller, {Kirstine N.}",
note = "{\textcopyright} 2022 by the American Diabetes Association.",
year = "2023",
doi = "10.2337/db22-0568",
language = "English",
volume = "72",
pages = "336–347",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "3",

}

RIS

TY - JOUR

T1 - The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and β-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery

AU - Hindsø, Morten

AU - Hedbäck, Nora

AU - Svane, Maria S.

AU - Møller, Andreas

AU - Martinussen, Christoffer

AU - Jørgensen, Nils B

AU - Dirksen, Carsten

AU - Gasbjerg, Lærke S

AU - Kristiansen, Viggo B.

AU - Hartmann, Bolette

AU - Rosenkilde, Mette M.

AU - Holst, Jens J

AU - Madsbad, Sten

AU - Bojsen-Møller, Kirstine N.

N1 - © 2022 by the American Diabetes Association.

PY - 2023

Y1 - 2023

N2 - Enhanced secretion of glucagon-like peptide-1 (GLP-1) seems to be essential for improved postprandial β-cell function after Roux-en-Y gastric bypass (RYGB) but is less studied after sleeve gastrectomy (SG). Moreover, the role of the other major incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), is relatively unexplored after bariatric surgery. We studied the effects of separate and combined GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) blockade during mixed meal tests in unoperated (CON), SG-operated, and RYGB-operated people with no history of diabetes. Postprandial GLP-1 concentrations were highest after RYGB but also higher after SG compared with CON. In contrast, postprandial GIP concentrations were lowest after RYGB. The effect of GLP-1R versus GIPR blockade differed between groups. GLP-1R blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the surgical groups but had no effect in CON. GIPR blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the CON and SG groups but had no effect in the RYGB group. Our results support that GIP is the most important incretin hormone in unoperated people, whereas GLP-1 and GIP are equally important after SG, and GLP-1 is the most important incretin hormone after RYGB.

AB - Enhanced secretion of glucagon-like peptide-1 (GLP-1) seems to be essential for improved postprandial β-cell function after Roux-en-Y gastric bypass (RYGB) but is less studied after sleeve gastrectomy (SG). Moreover, the role of the other major incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), is relatively unexplored after bariatric surgery. We studied the effects of separate and combined GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) blockade during mixed meal tests in unoperated (CON), SG-operated, and RYGB-operated people with no history of diabetes. Postprandial GLP-1 concentrations were highest after RYGB but also higher after SG compared with CON. In contrast, postprandial GIP concentrations were lowest after RYGB. The effect of GLP-1R versus GIPR blockade differed between groups. GLP-1R blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the surgical groups but had no effect in CON. GIPR blockade reduced β-cell glucose sensitivity and increased or tended to increase postprandial glucose responses in the CON and SG groups but had no effect in the RYGB group. Our results support that GIP is the most important incretin hormone in unoperated people, whereas GLP-1 and GIP are equally important after SG, and GLP-1 is the most important incretin hormone after RYGB.

U2 - 10.2337/db22-0568

DO - 10.2337/db22-0568

M3 - Journal article

C2 - 36478039

VL - 72

SP - 336

EP - 347

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -

ID: 331584952